CMCamila Mariot

Camila Mariot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camila Mariot has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reduction in sample recollection number following the implementation of automated pre-analytical interference detection in coagulation testing

    by Vitória Luiza Camargo Milczarski, Iuri Vicente Camargo Morkis, Camila da Silveira Mariot, Gabriel Giron Correa, Carine Ghem

    Background: Pre-analytical interferents such as hemolysis, lipemia, and icterus are major sources of error in coagulation testing and frequently lead to sample recollection. Visual inspection, although widely used, is subjective and may fail to identify unsuitable samples. Automated pre-analytical interferent detection using hemolysis, icterus, and lipemia (HIL) indices has been introduced to improve reliability and laboratory efficiency. Objective: Evaluate the impact of automated pre-analytical interferent detection on the number of sample recollections due to hemolysis in routine coagulation tests. Methods: A retrospective study compared two 1-year periods in a tertiary hospital laboratory. In 2022, samples were assessed by visual inspection using the STA-R® analyzer, while in 2023 automated inspection was implemented using the ACL Top® 750 system. Recollections due exclusively to hemolysis were analyzed for PT, aPTT, FV, fibrinogen, and D-dimer tests. Statistical analyses included binomial, Wald, and Student’s t tests, with p ≤ .005 considered significant. Results: A significant reduction in recollections was observed after the implementation of automated inspection (0.49% vs 0.35%; p < .001). PT showed a statistically significant decrease in recollections ( p = .003), while other tests demonstrated non-significant reductions. Monthly average recollections decreased by 18.9% ( p < .001). Annual costs related to recollections were reduced from US$ 638.49 to US$ 399.74, representing savings of US$ 238.75. A significant reduction was also observed in emergency department recollections. Conclusions: Automated pre-analytical interferent detection significantly reduced hemolysis-related recollections, costs, and subjectivity in coagulation testing, supporting its implementation as a valuable tool to improve laboratory workflow and result reliability.

  • Encapsulation of orlistat in biodegradable polymeric nanocapsules improves its cytotoxic effect against cervical cancer cells

    by Jéssica Nascimento, Isadora Do Canto Olegário, Camila Mariot, Thayse Viana de Oliveira, Paula dos Santos Chaves, Rafaela Oliveira, Edilene Gadelha de Oliveira, Silvia Stanisçuaski Guterres, Andréia Buffon, Diogo André Pilger, et al.


  • Open Access

    Fatty acid synthase as a potential new therapeutic target for cervical cancer

    by Jéssica Nascimento, Camila Mariot, Débora R.B. Vianna, Lúcia M. Kliemann, Paula S. Chaves, Massimo Loda, Andréia Buffon, Ruy C.R. Beck, Diogo A. Pilger

    Fatty acid synthase (FASN) is the rate-limiting enzyme for the de novo synthesis of fatty acids in the cytoplasm of tumour cells. Many tumour cells express high levels of FASN, and its expression is associated with a poorer prognosis. Cervical cancer is a major public health problem, representing the fourth most common cancer affecting women worldwide. To date, only a few in silico studies have correlated FASN expression with cervical cancer. This study aimed to investigate in vitro FASN expression in premalignant lesions and cervical cancer samples and the effects of a FASN inhibitor on cervical cancer cells. FASN expression was observed in all cervical cancer samples with increased expression at more advanced cervical cancer stages. The FASN inhibitor (orlistat) reduced the in vitro cell viability of cervical cancer cells (C-33A, ME-180, HeLa and SiHa) in a time-dependent manner and triggered apoptosis. FASN inhibitor also led to cell cycle arrest and autophagy. FASN may be a potential therapeutic target for cervical cancer, and medicinal chemists, pharmaceutical researchers and formulators should consider this finding in the development of new treatment approaches for this cancer type.